A Food and Drug Administration panel has ruled that the benefits of an experimental drug from Johnson & Johnson do not outweigh its risks, according to an agency spokeswoman.
FDA panel votes against J&J cancer drug benefitsCourtesy Newsvine - business Wed, 07/15/2009 - 10:28
A Food and Drug Administration panel has ruled that the benefits of an experimental drug from Johnson & Johnson do not outweigh its risks, according to an agency spokeswoman. Related itemsFDA panel wants more data on Genzyme cancer drug
FDA questions data for J&J ovarian cancer drug
FDA rejects GlaxoSmithKline nausea, vomiting drug
BlueAnt UNOTPBAX53 X5 Bluetooth Stereo Headphone...
Uniden TRU9496 2-Line Corded/Cordless Digital...
|
Popular by tags WeekMonth |
Post new comment